Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.

医学 多西紫杉醇 内科学 队列 乳腺癌 肿瘤科 癌症 转移性乳腺癌 曲妥珠单抗 化疗 临床终点 临床试验
作者
Keun Lee,Xiaojia Wang,Young-Hyuck Im,Xiaohua Zeng,Huiping Li,Kun Wang,Huiyan Li,Ping Zhou,Yuanyuan Bao,Zefei Jiang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 1031-1031 被引量:2
标识
DOI:10.1200/jco.2022.40.16_suppl.1031
摘要

1031 Background: HER2-targeted agents have improved outcomes in HER2-positive breast cancer, but some pts develop resistance, relapse, or do not respond to current 1L therapies. Zani, also known as ZW25, is a novel HER2-targeted bispecific antibody that binds to two distinct extracellular domains of HER2. In a Phase 1 trial (NCT02892123) zani was well tolerated and demonstrated preliminary antitumor activity as monotherapy/with chemotherapy in pts with pre-treated advanced HER2+ breast cancer. Methods: Cohort 1 of this ongoing open-label, Phase 1b/2 study (NCT04276493) is evaluating zani in combination with docetaxel as a 1L therapy in adult females with advanced HER2+ breast cancer who may have received prior neoadjuvant/adjuvant treatment. Cohort A pts received zani 30 mg/kg IV, Cohort B pts received zani 1800 mg IV, both with docetaxel 75 mg/m 2 IV Q3W. Primary endpoints were safety and investigator (INV)-assessed objective response rate (ORR) per RECIST v1.1. Secondary endpoints included INV-assessed duration of response (DoR), disease control rate (DCR) and progression-free survival (PFS). Results: As of Nov 26, 2021, 25 pts with a median age of 57.0 years (range: 33.0–80.0) were assigned to Cohort A (n=11) or B (n=14). Median study follow-up was 7.0 months (range: 1.1–17.4) and the median number of treatment cycles was 10 (range: 2–20), 16 (64.0%) pts remained on treatment. Of the 22-efficacy evaluable (EE) pts, confirmed ORR was 86.4% (95% CI: 65.1, 97.1). The 6 months PFS rate was 90.9% (95% CI: 68.3, 97.7). Efficacy data are summarized in Table 1. All pts experienced ≥ 1 treatment emergent adverse event (TEAE) and 17 (68.0%) pts experienced ≥ Grade 3 TEAEs. In total, 23 (92.0%) pts experienced treatment related TEAEs (trTEAEs), and 17 (68.0%) pts experienced ≥ Grade 3 trTEAEs. The most common trTEAEs were diarrhea (56.0%) and decreased neutrophil count (52.0%). Serious trTEAEs occurred in two (8.0%) pts, trTEAEs leading to treatment discontinuation occurred in one (4.0%) pt and no trTEAEs led to death. Conclusions: Zani and docetaxel combination demonstrated antitumor activity in 1L therapy for advanced HER2+ breast cancer, with a manageable safety profile. Clinical trial information: NCT04276493. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
乐乐的应助被康康采纳,获得10
1秒前
迷路丝袜发布了新的文献求助40
1秒前
刘很红发布了新的文献求助10
1秒前
神勇的煎蛋完成签到,获得积分10
1秒前
1秒前
wxyeah完成签到,获得积分10
1秒前
Cindycao完成签到,获得积分10
1秒前
2秒前
zhangl完成签到,获得积分10
2秒前
星辰大海的应助被研友_楼灵煌采纳,获得30
2秒前
2秒前
塔莉娅完成签到,获得积分10
2秒前
2秒前
我是老大的应助被大力文轩采纳,获得10
2秒前
华仔的应助被不辣的皮特采纳,获得10
3秒前
青青子衿完成签到,获得积分10
3秒前
xiaoxiaohei发布了新的文献求助10
3秒前
云为晓完成签到,获得积分10
3秒前
帅气yumin发布了新的文献求助10
3秒前
swaggy完成签到,获得积分10
3秒前
好好有宇宙完成签到 ,获得积分10
3秒前
h11的应助被是个狼火采纳,获得10
3秒前
徐徐完成签到 ,获得积分10
4秒前
4秒前
4秒前
Lucas的应助被青柳安采纳,获得10
4秒前
程天康发布了新的文献求助10
4秒前
核桃发布了新的文献求助10
4秒前
爱笑的山灵完成签到,获得积分10
5秒前
所所的应助被南山无梅落366采纳,获得10
5秒前
红红发布了新的文献求助10
5秒前
Zengjx完成签到,获得积分10
5秒前
顶真完成签到,获得积分10
5秒前
csdhdhsiuhihi完成签到,获得积分10
5秒前
6秒前
长情诗蕾发布了新的文献求助10
6秒前
Paz完成签到,获得积分10
6秒前
补丁完成签到,获得积分10
6秒前
猫ovo猫完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159633
求助须知:如何正确求助?哪些是违规求助? 9555145
关于积分的说明 21725138
捐赠科研通 7749593
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552345
邀请新用户注册赠送积分活动 2471619